Approved Professional Information

SCHEDULING STATUS

S2

1. NAME OF THE MEDICINE

DESLORATADINE GLENMARK (Tablet)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

DESLORATADINE GLENMARK: Each tablet contains 5 mg desloratadine.

Excipients with known effect:

Contains sugar: lactose monohydrate 98,80 mg per tablet.

For full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Tablet.

DESLORATADINE GLENMARK: Off-white to light pink, circular, biconvex with 'L5' debossed one side and plain on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

DESLORATADINE GLENMARK is indicated for the relief of symptoms associated with allergic rhinitis.

DESLORATADINE GLENMARK is also indicated for the short-term relief of symptoms associated with chronic idiopathic urticaria.

4.2 Posology and method of administration

Adults and adolescents (≥ 12 years of age):

Approved Professional Information

One **DESLORATADINE GLENMARK** tablet once a day regardless of mealtime for the relief of symptoms associated with allergic rhinitis (during intermittent and persistent rhinitis) and chronic idiopathic urticaria.

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week of for less than 4 weeks) should be managed in accordance with the evaluation of the patient's disease history. Treatment can be discontinued after symptoms are resolved and re-initiated upon their reappearance.

In persistent allergic rhinitis (presence of symptoms for more than 4 days or more per week or for more than 4 weeks), continued treatment may be proposed to patients during allergen exposure periods.

Improvement of symptoms associated with seasonal allergic rhinitis, usually becomes noticeable within 1 to 2 hours after administration of **DESLORATADINE GLENMARK**.

Method of administration

For oral use with or without food.

4.3 Contraindications

Hypersensitivity to desloratadine or to any of the inactive ingredients (see section 6.1).

4.4 Special warnings and precautions for use

In the case of severe renal insufficiency, **DESLORATADINE GLENMARK** should be taken with caution (see section 5.2).

DESLORATADINE GLENMARK should be taken with caution in patients with medical or familial history of seizures, and mainly young children (see section 4.8), being more susceptible to develop

new seizures with desloratadine, as in **DESLORATADINE GLENMARK** treatment. Health care providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.

Special Precautions

Safety and efficacy of **DESLORATADINE GLENMARK** Tablet in children under 12 years of age have not been established.

Safety and efficacy of desloratadine have not been established for treatment periods in excess of 4 weeks.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take **DESLORATADINE GLENMARK**.

4.5 Interaction with other medicines and other forms of interaction

Co-administration of desloratadine, as contained in **DESLORATADINE GLENMARK**, with ketoconazole increases the maximum desloratadine concentration (C_{max}) by 45 % and the area under the time concentration curve (AUC) by 37 %. Co-administration of desloratadine with erythromycin increased the C_{max} of desloratadine by 24 % and the AUC by 14 %. Co-administration of desloratadine, as contained in **DESLORATADINE GLENMARK**, with azithromycin resulted in an increase of both C_{max} (31 %) and AUC (12 %) of azithromycin. The increase in C_{max} and AUC of desloratadine, as contained in **DESLORATADINE GLENMARK**, when co-administered with either ketoconazole or erythromycin did not cause any clinically relevant adverse events in populations studied.

Co-administration of cimetidine with desloratadine, as contained in **DESLORATADINE GLENMARK**, did not significantly affect the pharmacokinetics of desloratadine. Co-administration of fluoxetine with desloratadine, as contained in **DESLORATADINE GLENMARK**, caused an increase in the C_{max} of

desloratadine by 15 % and an increase of 13 % in AUC and 17 % in C_{max} of 3-OH desloratadine respectively. The C_{max} and AUC of fluoxetine were reduced by 9 % and 11 % respectively. The corresponding mean parameters of norfluoxetine increased by 23 % and 18 % respectively, with co-administration of desloratadine, as contained in **DESLORATADINE GLENMARK**, and fluoxetine. No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose ketoconazole, and cimetidine interaction trials.

In a clinical pharmacology trial, desloratadine tablets taken concomitantly with alcohol did not potentiate the performance- impairing effects of alcohol (see section 5.1). However, cases of alcohol intolerance and intoxication have been reported during post-marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.

Paediatric population

Interaction studies have only been performed in adults.

4.6 Fertility, pregnancy and lactation

Pregnancy

Desloratadine, as in **DESLORATADINE GLENMARK**, were not found to be teratogenic in animal studies. The safe use of **DESLORATADINE GLENMARK** tablets during pregnancy has not been established and is therefore not recommended.

Breastfeeding

Desloratadine is excreted into breast milk, therefore the use of **DESLORATADINE GLENMARK** is not recommended in breastfeeding women.

Fertility

There are no data available on male and female fertility.

Approved Professional Information

4.7 Effects on ability to drive and use machines

Desloratadine, as in **DESLORATADINE GLENMARK** can cause dizziness and somnolence. It is recommended that patients be advised not to engage in activities requiring mental alertness, such as driving a vehicle or using machines, until they have established their own response to **DESLORATADINE GLENMARK**.

4.8 Undesirable effects

System organ class	Frequency	Adverse reactions
Immune system disorders	Less frequent	Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash and urticaria)
Metabolism and nutrition disorders	Frequency unknown	Increased appetite
Psychiatric disorders	Less frequent Frequency unknown	Hallucinations Abnormal behaviour, aggression
Nervous system disorders	Frequent Less frequent	Headache Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures
Cardiac disorders	Less frequent Frequency unknown	Tachycardia, palpitations QT prolongation
Gastrointestinal disorders	Frequent Less frequent	Dry mouth Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea
Hepatobiliary disorders	Less frequent Frequency unknown	Elevations of liver enzymes, increased bilirubin, hepatitis Jaundice
Skin and subcutaneous tissue disorders	Frequency unknown	Photosensitivity
Musculoskeletal and connective tissue disorders	Less frequent	Myalgia

Approved Professional Information

General disorders and administration site conditions	Frequent Frequency unknown	Fatigue Asthenia
Investigations	Frequency unknown	Increase in body mass

Paediatric population

Other undesirable effects reported during the post-marketing period in paediatric patients with an unknown frequency included QT prolongation, dysrhythmia, bradycardia, abnormal behaviour and aggression.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of **DESLORATADINE GLENMARK** is important. It allows continued monitoring of the benefit/risk balance of **DESLORATADINE GLENMARK**. Health care providers are asked to report any suspected adverse reactions via the **Adverse Drug Reaction Reporting Form**, found online under SAHPRA's publications: https://www.sahpra.org.za/Publications/Index/8

4.9 Overdose

The adverse event profile associated with overdosage, as seen during post-marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

Symptoms

Based on a multiple dose clinical trial, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.

Treatment

In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.

Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.

5. PHARMACOLOGICAL PROPERTIES

Category and class: A 5.7.1 Antihistaminics

Pharmacotherapeutic group: antihistamines – H1 antagonist, ATC code: R06A X27

5.1 Pharmacodynamic properties

Desloratadine is a non-sedating long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity. Desloratadine has demonstrated anti-allergic, antihistaminic and anti-inflammatory activity. After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors. It does not readily penetrate into the central nervous system.

In addition to antihistaminic activity, desloratadine has demonstrated anti-allergic and anti-inflammatory activity from numerous *in vitro* (mainly conducted on cells of human origin) and *in vivo* studies. These studies have shown that desloratadine inhibits the broad cascade of events that initiate and propagate allergic inflammation.

5.2 Pharmacokinetic properties

Absorption

Desloratadine plasma concentrations can be detected within 30 minutes of desloratadine administration. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg.

Distribution

Approved Professional Information

Desloratadine is moderately bound (83 % – 87 %) to plasma proteins. There is no evidence of clinically relevant medicine accumulation following once daily dosing of desloratadine (5 mg to 20 mg) for 14 days.

Biotransformation

The enzyme responsible for the metabolism of desloratadine has not yet been identified, and therefore some interactions with other medicines cannot be fully excluded. *In vivo* studies with specific inhibitors of CYP3A4 and CYP2D6 have shown that these enzymes are not important in the metabolism of desloratadine. Desloratadine does not inhibit CYP3A4 or CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.

Elimination

In a single-dose trial using a 7,5 mg dose of desloratadine, there was no effect of food (high-fat, high energy breakfast) on the disposition of desloratadine. In another study, grapefruit juice had no effect on the disposition of desloratadine.

Special patient populations

Renally impaired patients

The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single-dose study and one multiple-dose study. In the single-dose study, the exposure to desloratadine was approximately 2 and 2,5-fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple-dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1,5-fold greater in subjects with mild to moderate CRI and ~2,5-fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and C_{max} of desloratadine and 3-hydroxydesloratadine were not clinically relevant.

Approved Professional Information

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, silica colloidal anhydrous.

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months.

6.4 Special precautions for storage

Store at or below 25 °C.

Keep the blister strips in the original carton until required for use.

6.5 Nature and contents of container

DESLORATADINE GLENMARK (Tablets)

Pack size 1 x 10 tablets:

One blister strip of ten tablets in Aluminium/ Aluminium blisters i.e. cold formable Aluminium/ Hard tempered aluminium blister in a cardboard carton.

Pack size 3 x 10 tablets:

Three blister strips of ten tablets each in Aluminium/ Aluminium blisters i.e. cold formable Aluminium/ Hard tempered aluminium blister in a cardboard carton.

6.6 Special precautions for disposal and other handling

No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements.

Approved Professional Information

7. HOLDER OF CERTIFICATE OF REGISTRATION

Glenmark Pharmaceuticals South Africa (Pty) Ltd

34 Monte Carlo Crescent,

Block A, First floor,

Kyalami Park, Midrand,

1684

8. REGISTRATION NUMBER(S)

48/5.7.1/1257

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

19 April 2022

10. DATE OF REVISION OF TEXT

Not applicable